Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Researchers with City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...

The Risk Estimation of Tumor REcurrence After Transplant score accurately predicted hepatocellular carcinoma recurrence after liver transplantation.

Alibaba Group’s research arm, Damo Academy, has achieved a groundbreaking milestone in medical AI with its cancer detection ...

Symptoms, and Treatment Liver cancer is one of the most challenging forms of cancer, often developing quietly before showing any clear signs. It begins when abnormal cells form in the liver, a vital ...

Cold' tumors are resistant to common immunotherapies. Researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.

Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ-PKAc fusion oncoprotein. However, the underlying mechanism of DNAJ-PKAc’s ...

Multi-modal data integration of single-nuclei RNA and ATAC sequencing with spatial transcriptomics, provides new molecular insights into gene regulatory networks driving cell state transitions in ...

Hepatocellular carcinoma (HCC) represents the most prevalent malignancy in Egypt and globally. However, non-invasive diagnostic/prognostic biomarkers for early detection of HCC are still lacking.

Jazz Pharmaceuticals plc today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the ...